Albertsons (ACI) closes USD 17.31 on 02 Jan 2026: earnings Jan 07 may move stock
ACI stock closed at USD 17.31 on 02 Jan 2026 in the United States (NYSE), with volume at 5,530,980.00 shares and a day range of USD 17.05–17.35. Albertsons Companies, Inc. (ACI) reports earnings on 07 Jan 2026 before market open, making the upcoming print the likely near-term catalyst. Key fundamentals: EPS 1.69, PE ratio 10.24 and market cap 9510551718.00 USD. We walk through valuation, technicals and analyst targets to frame short-term trading risks and medium-term upside.
What happened today
ACI (Albertsons Companies, Inc.) closed at USD 17.31 on the NYSE after trading between USD 17.05 and USD 17.35. Volume was 5,530,980.00 versus an average volume of 8,779,809.00, showing below-average intraday activity. The stock’s 50-day average is USD 17.79 and its 200-day average is USD 19.79, which signals near-term pressure versus longer-term levels.
Earnings preview and near-term catalyst
Albertsons announces quarterly results on 07 Jan 2026 before market open (BMO). Street consensus expects modest EPS softness versus last year; the last set of analyst projections put consensus near the low single-digit revenue growth range. With EPS trailing 12 months at 1.69 USD and a current PE of 10.24, the earnings release will be evaluated for margin trends, pharmacy and fuel revenue performance, and same-store sales metrics.
Valuation and financials
Albertsons trades at a price-to-sales ratio of 0.12 and a price-to-book of 3.18, with trailing free cash flow yield near 9.95%. Net debt and leverage remain material: debt-to-equity is 4.97 and enterprise value is about 24518121833.00 USD, so interest and leverage sensitivity are key risks. The company pays a dividend of 0.60 USD per share, a 3.47% yield on the current price, and payout ratio is 0.33.
Technical snapshot
Short-term indicators show neutral to slightly bearish momentum: RSI 43.38 and MACD slightly negative. Bollinger Bands sit at USD 17.85 (upper) and USD 16.96 (lower) and ATR is 0.35 USD, indicating modest intraday volatility. Support lies near the 200-day average USD 19.79 and the year low USD 16.55 should act as a reference for risk management.
Meyka Grade, analyst targets and price outlook
Meyka AI rates ACI with a score out of 100: 79.53 — Grade B+ — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Analyst consensus price target median is USD 25.50 and the consensus target is USD 26.13, giving implied upside of about 50.97% versus the current USD 17.31. Wall Street consensus shows 7 Buy ratings and no Holds or Sells. Meyka AI’s forecast model projects a monthly target of USD 18.09 and a yearly model price near USD 17.32; forecasts are model-based projections and not guarantees.
Risks and opportunities
Opportunity: resilient grocery demand and diversification across pharmacy and fuel can support steady cash flow and the 3.47% yield is attractive for income-oriented investors. Risk: high leverage (debt-to-equity 4.97) constrains capital flexibility and raises sensitivity to margin pressure. Execution on cost controls and same-store sales will determine whether the stock re-rates toward analyst targets.
Final Thoughts
Key takeaways: ACI stock closed at USD 17.31 on 02 Jan 2026 ahead of an earnings report due 07 Jan 2026 BMO, making the release the immediate driver of short-term volatility. Valuation looks reasonable on a PE of 10.24 and a price-to-sales of 0.12, but high leverage (debt-to-equity 4.97) is the main structural risk. Analyst consensus price target near USD 26.13 implies about 50.97% upside from current levels, while Meyka AI’s forecast model projects a nearer-term monthly price of USD 18.09, an implied upside of 4.51% compared with today. Forecasts are model-based projections and not guarantees. For active traders the earnings print and guidance will be the trigger; for longer-term investors, improved cash flow conversion and measurable debt reduction remain the keys to justify a re-rating. This analysis uses market data from the NYSE in USD and is provided by Meyka AI as an AI-powered market analysis platform; it is not investment advice.
FAQs
Albertsons reports next on 07 Jan 2026 before market open (BMO). Expect management commentary on same-store sales, pharmacy trends and margin outlook to shape the near-term stock move.
ACI trades at USD 17.31 with a trailing PE of 10.24 and price-to-sales near 0.12. The company yields 3.47% with a payout ratio of 0.33, but leverage remains high.
Street consensus target is USD 26.13 (median USD 25.50), implying roughly 50.97% upside. Meyka AI’s monthly forecast is USD 18.09; forecasts are projections and not guarantees.
Primary risks are high leverage (debt-to-equity 4.97), margin pressure from inflation or wage costs, and lower-than-expected same-store sales. Execution on debt reduction is key.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
